The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: Implications for antiplatelet therapy

Blood

Volumn 115, Issue 5, 2010, Pages 1054-1061

  Dragani, Alfredo ^a   Pascale, Silvia ^a   Recchiuti, Antonio ^b   Mattoscio, Domenico ^b   Lattanzio, Stefano ^b   Petrucci, Giovanna ^c   Mucci, Luciana ^c   Ferrante, Elisabetta ^b   Habib, Aida ^d   Ranelletti, Franco O ^c   Ciabattoni, Giovanni ^b   Davì, Giovanni ^a,b   Patrono, Carlo ^c   Rocca, Bianca ^c  

^a SPIRITO SANTO HOSPITAL   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ETORICOXIB; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; TAUXIB; THIAZOLE ORANGE; THROMBOXANE; THROMBOXANE A2; THROMBOXANE B2 DERIVATIVE; UNCLASSIFIED DRUG; 11 DEHYDRO THROMBOXANE B2; 11-DEHYDRO-THROMBOXANE B2; DRUG DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRIDINE DERIVATIVE; SULFONE; THROMBOXANE B2;

ADD ON THERAPY; ADULT; ARTICLE; BIOSYNTHESIS; CELL REGENERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTHEMIA; URINARY EXCRETION; VOLUNTEER; BLOOD; DRUG COMBINATION; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; URINE;

ADULT; ASPIRIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PYRIDINES; SULFONES; THROMBOCYTHEMIA, ESSENTIAL; THROMBOXANE A2; THROMBOXANE B2; THROMBOXANES; TREATMENT OUTCOME;

EID: 77649228280     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-236679     Document Type: Article

References (50)

1. Schafer AI. Molecular basis of diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006;107(11):4214-4222. (Pubitemid 43801343)
2. Sanchez S, Ewton A. Essential thrombocythemia: a review of diagnostic and pathologic features. Arch Pathol Lab Med. 2006;130(8):1144-1150. (Pubitemid 44168782)
3. Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008;83(5):359-362.
4. Vannucchi A, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59(3):171-191.
5. Campbell P, Green A. Management of polycythemia vera and essential thrombocythemia. Hematology Am Soc Hematol Educ Program. 2005:201-208.
6. Birgegård G. Long term management of thrombocytosis in essential thrombocythemia. Ann Hematol. 2009;88(1):1-10.
7. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis and leukaemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645-1653.
8. Squizzato A, Romualdi E, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev. 2008;(2):CD006503.
9. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89(2):215-232. (Pubitemid 38796497)
10. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21(2):270-276. (Pubitemid 46158119)
11. 9/l be used as a diagnostic criterion in essential thrombocythaemia?: an analysis of the natural course including early stages. Br J Haematol. 1998;100(1):15-23.
12. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia at high risk of thrombosis. N Engl J Med. 1995;332(17):1132-1136.
13. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33-45.
14. De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors and effect of treatments. Haematologica. 2008;93(3):372-380.
15. Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Crit Rev Oncol Hematol. 1995;20(3):203-222.
16. Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008;112(8):3135-3137.
17. Griesshammer M, Beneke H, Nussbaumer B, Grünewald M, Bangerter M, Bergmann L. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythemia. Thromb Res. 1999;96(3):191-196. (Pubitemid 29531566)
18. Marchetti M, Falanga A. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders. Pathophysiol Haemost Thromb. 2008;36(3-4):148-159.
19. Rocca B, Ciabattoni G, Tartaglione R, et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost. 1995;74(5):1225-1230.
20. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482-2494.
21. Tefferi A. Essential thrombocythemia, polycythemia vera and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol. 2008;83(6):491-497.
22. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-124. (Pubitemid 38056222)
23. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373-2383.
24. Rocca B, Secchiero P, Ciabattoni G et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A. 2002;99(11):7634-7639. (Pubitemid 34568743)
25. Tanaka N, Sato T, Fujita H, Morita I. Constitutive expression and involvement of cyclooxygenase-2 in human megakaryocytopoiesis. Arterioscler Thromb Vasc Biol. 2004;24(3):607-612. (Pubitemid 38326160)
26. Guthikonda S, Alviar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008;52(9):743-749.
27. Guthikonda S, Lev EI, Patel R, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost. 2007;5(3):490-496. (Pubitemid 46680680)
28. Cailleteau C, Liagre B, Battu S, et al. Increased cyclooxygenase-2 and thromboxane synthase expression is implicated in diosgenin-induced megakaryocytic differentiation in human erythroleukemia cells. Anal Biochem. 2008;380(1):26-34.
29. Tripodo C, Florena AM, Porcasi R, et al. Constant detection of cyclooxygenase 2 in terminal stages of myeloid maturation. Acta Haematol. 2007;117(1):48-50. (Pubitemid 46012424)
30. Zetterberg E, Lundberg LG, Palmblad J. Expression of COX-2, tie-2 and glycodelin by megakaryocytes in patients with chronic myeloid leukaemia and polycythaemia vera. Br J Haematol. 2003;121(3):497-499. (Pubitemid 36628344)
31. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007;82(1-4):85-94.
32. Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol. 2009;53(8):667-677.
33. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097.
34. Patrono C, Ciabattoni G, Pinca E, et al. Low-dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17(3-4):317-327.
35. Ciabattoni G, Maclouf J, Catella F, FitzGerald GA, Patrono C. Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. Biochim Biophys Acta. 1987;918(3):293-297.
36. Karim S, Habib A, Lévy-Toledano S, Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem. 1996;271(20):12042-12048. (Pubitemid 26157282)
37. Rocca B, Spain LM, Ciabattoni G, Patrono C, FitzGerald GA. Differential expression and regulation of cyclooxygenase isozymes in thymic stromal cells. J Immunol. 1999;162(8):4589-4597. (Pubitemid 29314858)
38. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
39. Censarek P, Freidel K, Udelhoven M, et al. Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting. Thromb Haemost. 2004;92(5):925-928. (Pubitemid 39545513)
40. Ault KA, Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol. 1995;23(9):996-1001.
41. Hedegaard SS, Hvas AM, Grove EL, et al. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb Res. 2009;124(1):96-100.
42. Burke A, Smyth E, FitzGerald GA. Analgesicantipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Brunton LL, Lazo JS, Brown RY, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2006:673-715.
43. Bala M, Chin CN, Logan AT, et al. Acetylation of prostaglandin H2 synthase by aspirin is inhibited by redox cycling of the peroxidase. Biochem Pharmacol. 2008;75(7):1472-1481.
44. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69(6):1366-1372.
45. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325(18):1261-1266.
46. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest. 2008;133(6 suppl):199S-233S.
47. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72(6):1177-1184.
48. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2009;84(2):102-108
49. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest. 2008;133(6 suppl):234S-256S.
50. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia. 2008;51(3):383-390.